Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Immodulon Therapeutics Limited is currently processing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, though they are both located within 1 distinct art unit. Patricia Ann Duffy is the busiest examiner for the company, handling 1 pending office action.
The portfolio's activity is concentrated within 1 distinct art unit, despite the involvement of multiple examiners. This suggests that while the pending office actions fall under the same technical umbrella in Biotechnology & Pharmaceuticals, they are being evaluated by different individuals. Patricia Ann Duffy manages a portion of the 2 pending office actions currently active.
For a practitioner, the presence of multiple distinct examiners within a single art unit indicates a need to monitor different examiner styles within a single technical group. The pending office actions represent the entirety of the company's current prosecution workload. Patricia Ann Duffy is one of the examiners responsible for moving these matters forward.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252048 | MYCOBACTERIAL IMMUNOTHERAPY FOR TREATING CANCER | HAUK TEODORO, PRICILA NMN | 53d overdue |
| 18291950 | A MYCOBACTERIUM FOR USE IN CANCER THERAPY | DUFFY, PATRICIA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291950 | A MYCOBACTERIUM FOR USE IN CANCER THERAPY | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291950 | A MYCOBACTERIUM FOR USE IN CANCER THERAPY | DUFFY, PATRICIA ANN | 1645 | §102§112Other | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18252048 | MYCOBACTERIAL IMMUNOTHERAPY FOR TREATING CANCER | HAUK TEODORO, PRICILA NMN | 1645 | §103§112 | Final Rejection | 53d overdue | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial